Analytical Data
-
Gene name
PSMa5
- Application
-
Alternative Names
PSC5; Macropain zeta chain; Multicatalytic endopeptidase complex zeta chain; Proteasome zeta chain
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P28066
-
Expression Region
Met1~Ile241
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PSMa5, or Prostate-Specific Membrane Antigen 5, is a transmembrane protein predominantly expressed in prostate tissue, particularly in prostate cancer cells. Its overexpression in malignant tissues makes it a significant target for therapeutic intervention and diagnostic imaging in prostate cancer. Research on PSMa5 has gained momentum due to its potential role in tumor progression and its use as a biomarker for early detection and monitoring of prostate cancer. The protein’s unique structural and functional properties have been characterized through recombinant DNA technology, enabling the production of PSMa5 recombinant proteins for various studies. These advancements facilitate the exploration of PSMa5's interactions with other molecules and its function in cellular signaling pathways associated with cancer. Furthermore, the engineering of PSMa5 as a soluble form holds promise for the development of novel targeted therapies, such as antibody-drug conjugates and immunotherapies. Investigating PSMa5 through recombinant protein studies not only enhances our understanding of prostate cancer biology but also paves the way for innovative approaches in cancer treatment and personalized medicine. Given the increasing incidence of prostate cancer worldwide and the limitations of current diagnostic methods, research focusing on PSMa5 holds significant clinical relevance, with the potential to improve patient outcomes through better detection and targeted therapeutic strategies.
